Livin和Survivin在弥漫性大B细胞淋巴瘤组织中的表达及临床意义

Expression of Livin and Survivin in diffuse large B-cell lymphoma and their clinical significance

目的探讨Livin和Survivin在弥漫性大B细胞淋巴瘤组织中的表达及临床意义。方法收集初治的弥漫性大B细胞淋巴瘤组织标本40例作为实验组,同期收集21例反应性淋巴结炎患者的组织标本作为对照组,采用免疫组化PV-6000法检测Livin和Survivin的表达,并探讨Livin和Survivin与影响弥漫性大B细胞淋巴瘤预后因素的关系。结果实验组Livin的表达阳性率为62.5%(25/40),对照组为14.3%(3/21),两组比较,差异有统计学意义(P<0.05)。实验组Survivin的表达阳性率为67.5%(27/40),对照组为19.0%(4/21),两组比较,差异有统计学意义(P<0.05)。Livin和Sur-vivin均与淋巴瘤患者的体力状态ECOG(美国东部肿瘤协作组)评分、低密度脂蛋白水平、患者是否伴有B组临床症状及国际预后指数有关,与患者性别、年龄、临床分期及结外受累无关。Livin与Survivin在弥漫性大B细胞淋巴瘤组织中的表达无明显相关性(P>0.05)。结论 Livin和Survivin均与弥漫性大B细胞淋巴瘤的发生和发展有关,二者可作为评价弥漫性大B细胞淋巴瘤预后的生物学指标,调节Livin和Survivin的表达和功能可能成为治疗弥漫性大B细胞淋巴瘤的新途径。

Objective To investigate the expression of Livin and Survivin in diffuse large B-cell lymphoma（DLBCL） and their clinical significance. Methods The specimens were collected from 40 untreated cases of DLBCL as the experimenta group and contemporaneous 21 cases of benign lymph nodes hyperplasia （BLH） as the control group. The PV-6000 immunohistochem- ical staining was used to detect the expression of Livin and Survivin. The relation between Livin and Survivin with the factors in- fluencing the prognosis of DLBCL was investigated. Results The expression positive rate of Livin was 62.5% （25/40） in the ex- perimental group and 14.3% （3/21） in the control group with statistical difference （P〈0.05）. The expression positive rate of Sur- vivin was 67.5% （27/40） in the experimental group and 19.0% （4/21） in the control group with statistical difference （P〈0.05）. The expression of Livin and Survivin proteins was significantly related with PS ,LDH, group B symptoms and IPI （P〈0.05）. The expression of Livin and Survivin had no obvious relation with age, clinical stage and extranodal involvement. No obvious relation was found between the expressions of Livin and Survivin in DLBCL tissues. Conclusion Livin and Survivin play certain role in the oncogenesis and the progression of DLBCL and can be used as the biological indexes for evaluating the prognosis of DLBCL. Modulation of Livin and survivin expression or function may provide a novel approach for the therapy in the patients with DLBCL.